Paquinimod
- Generic Name
- Paquinimod
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N2O3
- CAS Number
- 248282-01-1
- Unique Ingredient Identifier
- HB76GLG27V
- Background
Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.
An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 9
- Registration Number
- NCT01487551
Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT00997100
- Locations
- 🇸🇪
Lars Rönnblom M.D., Uppsala, Sweden
🇸🇪Iva Gunnarsson M.D., Stockholm, Sweden
🇩🇰Soren Jacobsen, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.